News

Treatment with the investigational drug FHD-286 exhibits positive results in patients with metastatic uveal melanoma and will be explored further in acute myeloid leukemia and myelodysplastic syndrome.

A phase 1 study is assessing the safety and tolerability of briquilimab in patients with lower-risk myelodysplastic syndrome.

A fast track designation has been granted by the FDA to quaratusugene ozeplasmid with atezolizumab for the treatment patients with extensive-stage small cell lung cancer.

The phase 2b VIRAGE study will investigate the safety and efficacy of VCN-01 plus standard chemotherapy in patients with first-line pancreatic ductal adenocarcinoma.

Jennifer R. Brown, MD, PhD, highlights the results from the phase 3 ALPINE study evaluating the treatment with zanubrutinib for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

E-602 represents the first glyco-immune checkpoint inhibitor and the early safety as well as translational immunology associated with the treatment in patients with advanced cancer is promising, according to Jason Luke, MD, FACP.

Topline results from the EPCORE NHL-1 trial showed promising efficacy findings and no new safety signals with epcoritamab in a cohort of 128 patients with relapsed/refractory follicular lymphoma.

According to the developer of TTI-101, the REVERT-Liver Cancer trial is the second of three phase 2 trials involving the agent.

Durable responses in patients with metastatic pancreatic ductal adenocarcinoma treated with mitazalimab plus chemotherapy have led to discussions with regulatory authorities.

Updates to the NCCN guidelines will help clinicians treat their patients with acute lymphoblastic leukemia, B-cell lymphomas, pediatric acute lymphoblastic leukemia, and pediatric aggressive mature B-cell lymphomas on high-dose methotrexate.

The National Comprehensive Cancer Network has updated its guidelines to include the recently approved T-cell engaging bispecific antibody epcoritamab for B-cell lymphomas.

In an interview with Targeted Oncology, Benjamin Besse, MD, PhD, discussed recently reported results from the phase 1/1b CHRYSALIS-2 of amivantamab and lazertinib in patients with EGFR-mutated non–small cell lung cancer.

Promise has been shown with serplulimab plus HLX04 for the treatment of advanced hepatocellular carcinoma, according to phase 2 international research.

Although drug shortages are not new, the number of drugs involved is increasing and resolutions seem to take longer, and oncology care is often affected by these shortages.

Among patients with unresectable or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma, envafolimab generated positive efficacy data with a well-tolerated safety profile.

The speed at which immunotherapy is adopted by oncology practices depends on their size, location, and affiliation, according to an analysis.

In an interview with Targeted Oncology, Jorge Cortes, MD, highlights the use of olutasidenib in patients with relapsed/refractory acute myeloid leukemia.

Very high tumor burden is a potential biomarker that may predict response to anti–PD-L1 therapy in patients of Asian descent across cancer types.

Hatem Soliman, MD, discusses fam-trastuzumab deruxtecan-nxki and its importance for patients with HER2-positive breast cancer.

In an interview with Targeted Oncology, Ajay K. Nooka, MD, MPH, FACP, discussed data from a pooled analysis of studies from the MagnetisMM program evaluating erlanatamab in relapsed/refractory multiple myeloma.

Karim Fizazi, MD, discusses the toxicities seen with the combination of talazoparib plus enzalutamide.

Melissa Johnson, MD, discussed SHP2 inhibitors with Targeted Therapies in Oncology.

ADX-2191 will not be granted approval by the FDA due to the results of the phase 3 GUARD trial.

Druggable targets for patients with gastrointestinal cancers were discussed during the 20th Annual Meeting of the International Society of Gastrointestinal Oncology.

The phase 1 study is evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of KT-253 monotherapy in patients with acute myeloid leukemias.

Karim Fizazi, MD, discusses findings from the phase 3 TALAPRO-2 trial which support the recent FDA approval of talazoparib plus enzalutamide in homologous recombination repair gene-mutated metastatic castration resistant prostate cancer.

Ruchi Garg, MD, discusses current treatment options and strategies being utilized for patients with endometrial cancer.

Benjamin Besse, MD, PhD, discusses the main findings and next steps of the phase 1/1b CHRYSALIS-2 study in EGFR-mutated non–small cell lung cancer.

Additional data have led to a full FDA approval for blinatumomab.

VEGFR inhibitors, mTOR inhibitors, and immune checkpoint inhibitors have been studied as adjuvant therapy for patients with RCC. However, conflicting data from phase 3 trials have left investigators unclear on what their role is.